HomeTagsJohnson & Johnson

Tag: Johnson & Johnson

biotech

Johnson & Johnson prostate cancer drug receives CHMP positive opinion

Jim Cornall - February 5, 2026

biotech

First precision therapy prostate cancer drug approved

Jim Cornall - December 17, 2025

biotech

CRS programme to feature Poolbeg Pharma trial

Jim Cornall - December 11, 2025

biotech

“Turning point in how we treat EGFR-mutated lung cancer”

Jim Cornall - September 10, 2025

biotech

Johnson & Johnson aiming to revolutionise plaque psoriasis treatment

Jim Cornall - July 24, 2025

biotech

Johnson & Johnson receives Priority Review for high-risk non-muscle invasive bladder cancer treatment

Jim Cornall - July 22, 2025

- Advertisement -

spot_img

Latest Articles

biotech

Kither Biotech completes phase 1 trial of inhaled peptide therapy for respiratory diseases

biotech

Houdini Bio launches to solve therapeutic and commercial genetic medicine bottlenecks

biotech

Base to Base biotech podcast 64: Solving logistics challenges

biotech

Preclinical results for novel therapeutic candidate for rare neurodevelopmental disorders

biotech

Breakthrough in personalised treatments for lung cancer